---
title: "盈利快報：Hims & Hers Health 第一季度盈利因利潤壓力受到影響；第二季度收入有所提升"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/285996549.md"
description: "Hims & Hers Health 報告稱第一季度的收益受到利潤壓力的影響，但預計第二季度收入將增加。該公司正在經歷穩定，這可能導致市場緊縮。最近關於 GLP-1 複合藥物的 FDA 裁決可能對 Hims 有利，並且評級上調已被提及。此外，還提供了關於被做空醫療股的見解"
datetime: "2026-05-11T20:59:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285996549.md)
  - [en](https://longbridge.com/en/news/285996549.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285996549.md)
---

# 盈利快報：Hims & Hers Health 第一季度盈利因利潤壓力受到影響；第二季度收入有所提升

More on Hims & Hers Health Hims Earnings: Stability Could Trigger A Squeeze Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade) Hims & Hers Health Q1 2026 Earnings Preview Most and least shorted mid-to mega-cap healthcare stocks in May

### 相關股票

- [HIMS.US](https://longbridge.com/zh-HK/quote/HIMS.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [IHF.US](https://longbridge.com/zh-HK/quote/IHF.US.md)
- [HIMZ.US](https://longbridge.com/zh-HK/quote/HIMZ.US.md)
- [HIMY.US](https://longbridge.com/zh-HK/quote/HIMY.US.md)
- [NVO.US](https://longbridge.com/zh-HK/quote/NVO.US.md)

## 相關資訊與研究

- [瑞銀上調爵士製藥評級：核心業務韌性強勁，新藥 Ziihera 成增長引擎](https://longbridge.com/zh-HK/news/286920691.md)
- [HIMS 又崩了！](https://longbridge.com/zh-HK/news/286084969.md)
- [保柏：港人深圳求醫年 70 萬人次](https://longbridge.com/zh-HK/news/286818539.md)
- [快閃英法參訪...歐洲在宅醫療模式大開眼界 石崇良：進速升級長照 3.0](https://longbridge.com/zh-HK/news/286931217.md)
- [沒住院就不理賠、傳統醫療險跟不上醫療變革 金管會 3 個月盤點現有保單](https://longbridge.com/zh-HK/news/287006784.md)